The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Eli Lilly's stock price surged following impressive late-stage trial results for its next-generation weight-loss drug. The company also reported that its drug Jaypirca significantly reduced the risk of disease progression in CLL/SLL patients. Furthermore, Eli Lilly expanded its portfolio by acquiring 4E Therapeutics, a developer of non-addictive painkillers.